Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37033 | 0.89 | HTR6 (0.42) | CA2HSD11B1CA1CA9CA5A | |
| SCHEMBL503373 | 0.84 | PKM (0.46) | MEN1KMT2AHSD11B1 | |
| SCHEMBL4643793 | 0.84 | CA1 (0.46) | MEN1KMT2ACA2HSD11B1CA1 | |
| SCHEMBL3130157 | 0.84 | PKM (0.46) | MEN1KMT2AHSD11B1 | |
| SCHEMBL36148 | 0.83 | HTT (0.45) | MEN1KMT2ACA2HSD11B1CA1 | |
| SCHEMBL1261245 | 0.83 | HSD11B1 (0.45) | MEN1KMT2ACA2HSD11B1CA1 | |
| SCHEMBL3139517 | 0.83 | TDP1 (0.46) | MEN1KMT2ACA2HSD11B1CA1 | |
| SCHEMBL444803 | 0.83 | PTGS2 (0.44) | HSD11B1 | |
| SCHEMBL548280 | 0.83 | ESR1 (0.42) | MEN1KMT2ACA2HSD11B1CA1 | |
| SCHEMBL3136958 | 0.83 | HTT (0.45) | MEN1KMT2ACA2HSD11B1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271657-B1 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME | CRYSTAL BIOSCIENCE INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9309358-B2 | Crosslinkable siloxanes by acid-catalyzed polymerization of oxasilacycles | WACKER CHEMIE AG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150175749-A1 | CROSSLINKABLE SILOXANES BY ACID-CATALYZED POLYMERIZATION OF OXASILACYCLES | WACKER CHEMIE AG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8455561-B2 | Method for the production of foams on silicone basis | WACKER CHEMIE AG (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8415173-B2 | Gel microdrop composition and method of using the same | CRYSTAL BIOSCIENCE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120077714-A1 | Mass Spectrometry Based Particle Separation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-29 | — | — | US | disclosed |
| US-20120058903-A1 | Gel Microdrop Composition and Method of Using the Same | CRYSTAL BIOSCIENCE INC. | 2012-03-08 | — | — | US | disclosed |
| US-8030095-B2 | Gel microdrop composition and method of using the same | CRYSTAL BIOSCIENCE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110124752-A1 | METHOD FOR THE PRODUCTION OF FOAMS ON SILICONE BASIS | WACKER CHEMIE AG (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-2271657-A2 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME | Crystal Bioscience Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100331483-A1 | CURABLE POLYMER MIXTURES | WACKER CHEMIE AG (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100092955-A1 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME | CRYSTAL BIOSCIENCE INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2009111014-A2 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME | CRYSTAL BIOSCIENCE INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1674855-A2 | Addressable recovery of bound analytes from an evanescent wave sensor | AGILENT TECHNOLOGIES, INC. (A Delaware Corporation) (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060128031-A1 | Addressable recovery of bound analytes from an evanescent wave sensor | AGILENT TECHNOLOGIES, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175749-A1 | CROSSLINKABLE SILOXANES BY ACID-CATALYZED POLYMERIZATION OF OXASILACYCLES | MCM4, ITGB4, ITGA4 | IDO1 2494/4885MEN1 1910/4885KMT2A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.